328 related articles for article (PubMed ID: 20564072)
1. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life.
Joshi SS; Ortiz S; Witherspoon JN; Rademaker A; West DP; Anderson R; Rosenbaum SE; Lacouture ME
Cancer; 2010 Aug; 116(16):3916-23. PubMed ID: 20564072
[TBL] [Abstract][Full Text] [Related]
2. Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy.
Tejwani A; Wu S; Jia Y; Agulnik M; Millender L; Lacouture ME
Cancer; 2009 Mar; 115(6):1286-99. PubMed ID: 19170238
[TBL] [Abstract][Full Text] [Related]
3. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic.
Rosen AC; Case EC; Dusza SW; Balagula Y; Gordon J; West DP; Lacouture ME
Am J Clin Dermatol; 2013 Aug; 14(4):327-33. PubMed ID: 23625802
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors.
Osio A; Mateus C; Soria JC; Massard C; Malka D; Boige V; Besse B; Robert C
Br J Dermatol; 2009 Sep; 161(3):515-21. PubMed ID: 19466958
[TBL] [Abstract][Full Text] [Related]
5. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy.
Eilers RE; Gandhi M; Patel JD; Mulcahy MF; Agulnik M; Hensing T; Lacouture ME
J Natl Cancer Inst; 2010 Jan; 102(1):47-53. PubMed ID: 20007525
[TBL] [Abstract][Full Text] [Related]
6. Higher severity grade of erlotinib-induced rash is associated with lower skin phototype.
Luu M; Boone SL; Patel J; Sullivan P; Rademaker AW; Balagula Y; Lacouture ME
Clin Exp Dermatol; 2011 Oct; 36(7):733-8. PubMed ID: 21689147
[TBL] [Abstract][Full Text] [Related]
7. Quality-of-life assessment in patients with pemphigus using a minimum set of evaluation tools.
Paradisi A; Sampogna F; Di Pietro C; Cianchini G; Didona B; Ferri R; Abeni D; Tabolli S
J Am Acad Dermatol; 2009 Feb; 60(2):261-9. PubMed ID: 19004524
[TBL] [Abstract][Full Text] [Related]
8. Protease inhibitor combination therapy, severity of illness, and quality of life among children with perinatally acquired HIV-1 infection.
Storm DS; Boland MG; Gortmaker SL; He Y; Skurnick J; Howland L; Oleske JM;
Pediatrics; 2005 Feb; 115(2):e173-82. PubMed ID: 15629958
[TBL] [Abstract][Full Text] [Related]
9. Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer.
Lacouture ME
Cancer Nurs; 2007; 30(4 Suppl 1):S17-26. PubMed ID: 17666987
[TBL] [Abstract][Full Text] [Related]
10. The impact of dermatological toxicities of anti-cancer therapy on the dermatological quality of life of cancer patients.
Ra HS; Shin SJ; Kim JH; Lim H; Cho BC; Roh MR
J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):e53-9. PubMed ID: 22329482
[TBL] [Abstract][Full Text] [Related]
11. Health related quality of life after orthotopic neobladder construction and its comparison with normative values in the Japanese population.
Yoneda T; Adachi H; Urakami S; Kishi H; Shigeno K; Shiina H; Igawa M
J Urol; 2005 Nov; 174(5):1944-7. PubMed ID: 16217363
[TBL] [Abstract][Full Text] [Related]
12. Rectal cancer therapy: decision making on basis of quality of life?
Harisi R; Bodoky G; Borsodi M; Flautner L; Weltner J
Zentralbl Chir; 2004 Apr; 129(2):139-48. PubMed ID: 15106048
[TBL] [Abstract][Full Text] [Related]
13. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results.
Boone SL; Rademaker A; Liu D; Pfeiffer C; Mauro DJ; Lacouture ME
Oncology; 2007; 72(3-4):152-9. PubMed ID: 18160805
[TBL] [Abstract][Full Text] [Related]
14. Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity.
Staubach P; Eckhardt-Henn A; Dechene M; Vonend A; Metz M; Magerl M; Breuer P; Maurer M
Br J Dermatol; 2006 Feb; 154(2):294-8. PubMed ID: 16433799
[TBL] [Abstract][Full Text] [Related]
15. Psychosocial impact of cutaneous toxicities associated with epidermal growth factor receptor-inhibitor treatment.
White KJ; Roydhouse JK; Scott K
Clin J Oncol Nurs; 2011 Feb; 15(1):88-96. PubMed ID: 21278044
[TBL] [Abstract][Full Text] [Related]
16. Oral mucositis and quality of life of Hong Kong Chinese patients with cancer therapy.
Cheng KK
Eur J Oncol Nurs; 2007 Feb; 11(1):36-42. PubMed ID: 17258505
[TBL] [Abstract][Full Text] [Related]
17. A pilot quality-of-life instrument for pruritus.
Desai NS; Poindexter GB; Monthrope YM; Bendeck SE; Swerlick RA; Chen SC
J Am Acad Dermatol; 2008 Aug; 59(2):234-44. PubMed ID: 18550210
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life.
Hundley JL; Carroll CL; Lang W; Snively B; Yosipovitch G; Feldman SR; Jorizzo JL
J Am Acad Dermatol; 2006 Feb; 54(2):217-20. PubMed ID: 16443050
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous reactions to epidermal growth factor receptor inhibitors.
Pomerantz RG; Mirvish ED; Geskin LJ
J Drugs Dermatol; 2010 Oct; 9(10):1229-34. PubMed ID: 20941947
[TBL] [Abstract][Full Text] [Related]
20. Treatment of epidermal growth factor receptor antagonist-induced skin rash: results of a survey among German oncologists.
Hassel JC; Kripp M; Al-Batran S; Hofheinz RD
Onkologie; 2010; 33(3):94-8. PubMed ID: 20215799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
